DOI: https://doi.org/10.29296/24999490-2019-01-06

I.M. Kvetnoy(1–3), V.O. Polyakova(1–3), Yu.S. Krilova(2, 6), N.S. Linkova(1, 4), U.F. Gashimova(5), A.M. Gadzhiev(5), E.A. Karpasova(1), E.S. Mironova(1), V.A. Bunin(1) 1-Saint Petersburg Institute of Bioregulation and Gerontology, Dynamo pr., 3, Saint Petersburg, 197110, Russian Federation; 2-D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology, Mendeleyevskaya line, 3, Saint Petersburg, 199034, Russian Federation; 3-Saint Petersburg State University, Universitetskaya Embankment, 7–9, Saint Petersburg, 199034, Russian Federation; 4-Peter the Great Saint Petersburg Polytechnic University, Polytechnicheskaya Str. 29, Saint Petersburg, 195251, Russian Federation; 5-Garayev Institute of Physiology, Azerbaijan National Academy of Sciences, Baku, Sharuphzade str., 78, AZ1100, Azerbaijan 6Pavlov First Saint Petersburg State Medical University, L'vaTolstogo str. 6–8, Saint Petersburg, Russian Federation, 197022 E-mail: miayy@yandex.ru

The task of molecular vital diagnosis is to search for peripheral tissues for the verification of biomarkers with the aim of optimization of diagnosis and evaluation of the effectiveness of treatment of socially significant diseases including cardiovascular pathology. Аim of the work was to study the expression of IL6 cytokine, ICAM-1 adhesion molecule and troponin-1 in the buccal epithelium (BE) in middle age, elderly and senile patients with atherosclerosis of the lower limbs and without cardiovascular pathology. Material and methods. The material of BE in 64 healthy donors without cardiovascular pathology and 72 patients with atherosclerosis of the lower limbs was collected from middle-aged (53,2±2,4 years), elderly (68,1±2,3 years) and senile (78,7±3,6 years) age patients. BE was examined by an immunocytochemical method using confocal microscopy. Results. IL6 and ICAM-1 molecules are the most informative for evaluating the aging of the cardiovascular system in healthy cases, and can also be used to diagnose atherosclerosis of the lower limbs in patients of the middle, elderly and senile age.Сonclusion. In this case, troponin-1 has a diagnostic ability for atherosclerosis of the lower limbs only in elderly and senile individuals.
cardiovascular pathology, atherosclerosis, buccal epithelium, IL6, ICAM-1, troponin-1

Список литературы: 
  1. Van Camp G. Cardiovascular disease prevention. Acta Clin Belg. 2014; 69 (6): 407–11.
  2. Ferrières J. A paradigm shift in the treatment of atherosclerosis. Arch Cardiovasc Dis. 2015; 108 (6–7): 337–9.
  3. Drobotya N.V., Guseynova E`.Sh., Pirozhenko A.A. Sovremennye podohody k ocenke zhestkosti arterial`noy stenki v praktike vracha-terapevta. Metodicheskie rekomendacii. Rostovskiy GMU Minzdrava Rossii, FPK i PPS. 2014; 32. [Drobotya N.V., Guseinova E.S., Pirozhenko A.A. Modern approaches to assessing the rigidity of the arterial wall in the practice of a physician-therapist. Guidelines. Rostov State Medical University of the Ministry of Health of Russia, FPK and PPS. 2014; 32 (in Russian)]
  4. Zhang Q., Qian G., Ding Z. Xuemaitong granules attenuate carotid atherosclerosis by decreasing the expression of CD14+CD16+ monocytes, IL-6, TNF-α, and hsCRP. Genet Mol Res. 2014; 13 (3): 7519–27.
  5. Cronjé H.T., Nienaber-Rousseau C., Zandberg L., de Lange Z., Green F.R., Pieters M. Fibrinogen and clot-related phenotypes determined by fibrinogen polymorphisms: Independent and IL-6-interactive associations. PLoS One. 2017; 12 (11): 3.
  6. Held C., White H.D., Stewart R.A.H. Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences from the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial. Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease. 2017; 6 (10): 17–28.
  7. Cavieres V., Valdes K., Moreno B., Moore-Carrasco R., Gonzalez D.R. Vascular hypercontractility and endothelial dysfunction before development of atherosclerosis in moderate dyslipidemia: role for nitric oxide and interleukin-6. Am J Cardiovasc Dis. 2014; 4 (3): 114–22.
  8. Aulin J., Siegbahn A., Hijazi Z., Ezekowitz M.D., Andersson U., Connolly S.J., Huber K., Reilly P.A., Wallentin L., Oldgren J. Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation. Am. Heart J. 2015; 170 (6): 1151–60.
  9. Chang C.C., Chu C.F., Wang C.N., Wu H.T., Bi K.W., Pang J.H., Huang S.T. The anti-atherosclerotic effect of tanshinone IIA is associated with the inhibition of TNF-α-induced VCAM-1, ICAM-1 and CX3CL1 expression. Phytomedicine. 2014; 21 (3): 207–16.
  10. Jiang Y., Jiang L.L., Maimaitirexiati X.M., Zhang Y., Wu L. Irbesartan attenuates TNF-α-induced ICAM-1, VCAM-1, and E-selectin expression through suppression of NF-κB pathway in HUVECs. Eur. Rev. Med. Pharmacol Sci. 2015; 19 (17): 3295–302.
  11. Yang M., Fu Z., Zhang Q., Xin Y., Chen Y., Tian Y. Association between the polymorphisms in intercellular adhesion molecule-1 and the risk of coronary atherosclerosis: a case-controlled study. PLoS One. 2014; 9 (10): 13–20.
  12. Conti A., Angeli E., Scorpiniti M., Alesi A., Trausi F., Lazzeretti D., Padeletti L., Gensini G.F. Coronary atherosclerosis and adverse outcomes in patients with recent-onset atrial fibrillation and troponin rise. Am. J. Emerg. Med. 2015; 33 (10): 1407–13.
  13. Harvell B., Henrie N., Ernst A.A., Weiss S.J., Oglesbee S., Sarangarm D., Hernandez L. The meaning of elevated troponin I levels: not always acute coronary syndromes. Am. J. Emerg Med. 2016; 34 (2): 145–8.
  14. Wallace K.A., Goldschmidt M.H., Patel R.T. Converting fluid-based cytologic specimens to histologic specimens for immunohistochemistry. Vet Clin. Pathol. 2015; 44 (2): 303–9.
  15. Esquivias López-Cuervo J., Montalbán Beltran E., Cuadros Lopez J.L., Alonso Castillo A., Nieto Sanchez T. Preliminary study of a new, fully automated system for liquid-based cytology: the NovaPrep® processor system. Acta Cytol. 2011; 55 (3): 281–6.
  16. Tanaka T., Narazaki M., Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb. Perspect. Biol. 2014; 12: 47–59.
  17. Hartman J., Frishman W.H. Inflammation and atherosclerosis: a review of the role of interleukin-6 in the development of atherosclerosis and the potential for targeted drug therapy. Cardiol. Rev. 2014; 22 (3): 147–51.